نتائج البحث - Anthony Turkiewicz

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

    4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis حسب Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna D. Gladman, Alice B. Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, J. Wollenhaupt, Philip J. Mease

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

    Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure حسب Philip J. Mease, Atul Deodhar, Roy Fleischmann, J. Wollenhaupt, Dafna D. Gladman, Piotr Leszczyński, Pavel Vítek, Anthony Turkiewicz, Majed Khraishi, Oliver FitzGerald, Robert Landewé, M. de Longueville, Bengt Hoepken, Luke Peterson, D. van der Heijde

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

    Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations حسب Lihi Eder, Ashish Jacob Mathew, Philippe Carron, Heidi Bertheussen, Juan D. Cañete, May Azem, Andrea Delle Sedie, Carlo Salvarani, Roberto Ranza, Ashley Elliott, Anthony Turkiewicz, Roberto Acayaba de Toledo, Hülya Bükülmez, Maria Stoenoiu, Arthur M. Mandelin, Michaela Koehm, Chris A. Lindsay, Evan Siegel, Philip J. Mease

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

    Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis حسب John H. Stone, Peter A. Merkel, Robert Spiera, Philip Seo, Carol A. Langford, Gary S. Hoffman, Cees G. M. Kallenberg, E. William St. Clair, Anthony Turkiewicz, Nadia K. Tchao, Lisa Webber, Linna Ding, Lourdes P. Sejismundo, Kathleen Mieras, David Weitzenkamp, David Iklé, Vicki Seyfert‐Margolis, Mark Mueller, Paul Brunetta, Nancy B. Allen, Fernando C. Fervenza, Duvuru Geetha, Karina A. Keogh, Eugene Y. Kissin, Paul A. Monach, Tobias Peikert, Coen A. Stegeman, Steven R. Ytterberg, Ulrich Specks

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: